An Update on the Molecular Pathology of Metaplastic Breast Cancer

QR Code

An Update on the Molecular Pathology of Metaplastic Breast Cancer

Amy E McCart Reed,1 Emarene M Kalaw,1 Sunil R Lakhani1,2 1UQ Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia; 2Pathology Queensland, Brisbane, Queensland, AustraliaCorrespondence: Sunil R Lakhani Email s.lakhani@uq.edu.auAbstract: Metaplastic breast cancer...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	McCart Reed AE, Kalaw EM, Lakhani SR
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2021
Sujets:	metaplastic triple negative-breast cancer precision oncology Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/ac6549a58d8e4fce80894fa9f6c0c0f9
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Metaplastic breast carcinoma with upper limb gangrene
par: Rajan R, et autres
Publié: (2017)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
par: Marina K. Ibragimova, et autres
Publié: (2021)

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
par: Hana Kim, et autres
Publié: (2021)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
par: Fleisher B, et autres
Publié: (2016)

Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
par: Xupeng Bai, et autres
Publié: (2021)

Antiangiogenic therapy for breast cancer with triple negative phenotype
par: Inna P. Ganshina, et autres
Publié: (2021)

Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers
par: Al-saraireh YM, et autres
Publié: (2021)

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
par: Luis de la Cruz-Merino, et autres
Publié: (2021)

Effect of statins on breast cancer recurrence and mortality: a review
par: Van Wyhe RD, et autres
Publié: (2017)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
par: Miyuki Kitahara, et autres
Publié: (2021)

Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
par: Ilie SM, et autres
Publié: (2018)

Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer
par: Alyssa Vito, et autres
Publié: (2021)

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
par: Ieni A, et autres
Publié: (2016)

Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells
par: Cook MT, et autres
Publié: (2016)

Non-Coding RNAs Associated With Radioresistance in Triple-Negative Breast Cancer
par: Alberto Aranza-Martínez, et autres
Publié: (2021)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
par: da Silva JL, et autres
Publié: (2021)

Molecular Classification of Breast Cancer Utilizing Long Non-Coding RNA (lncRNA) Transcriptomes Identifies Novel Diagnostic lncRNA Panel for Triple-Negative Breast Cancer
par: Hibah Shaath, et autres
Publié: (2021)

Opportunities for metastatic triple negative breast cancer therapy
par: Inna P. Ganshina, et autres
Publié: (2021)

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
par: Inna P. Ganshina, et autres
Publié: (2021)

Assessing Clinicopathological Features and Prognosis of Triple-Negative Breast Cancer Patients: A Single-Center Study in Turkey
par: Saliha Karagöz Eren, et autres
Publié: (2021)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
par: Giacomo Barchiesi, et autres
Publié: (2021)

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
par: Jesse Lopes da Silva, et autres
Publié: (2021)

Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer
par: Peng Su, et autres
Publié: (2021)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
par: Yuanfang Xin, et autres
Publié: (2021)

The Potential Prognostic Role of Oligosaccharide-Binding Fold-Containing Protein 2A (OBFC2A) in Triple-Negative Breast Cancer
par: Qianxue Wu, et autres
Publié: (2021)

Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells
par: Chia-Che Chang, et autres
Publié: (2021)

Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients
par: Wen S, et autres
Publié: (2020)

Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer
par: Hongyuan Zhao, et autres
Publié: (2021)

Palmatine sensitizes chemoresistant triple negative breast cancer cells via efflux inhibition of multidrug resistant protein 1.
par: Selase Ativui, et autres
Publié: (2021)

Tumor suppressive function of Matrin 3 in the basal-like breast cancer
par: Yang,Jaehyuk, et autres
Publié: (2020)

Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits
par: Chiara Giacomelli, et autres
Publié: (2021)

Prognostic and clinicopathological values of tissue expression of MFAP5 and ITM2A in triple-negative breast cancer: an immunohistochemical study
par: Abdulwahab Abuderman, et autres
Publié: (2020)

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
par: Aurelia Noske, et autres
Publié: (2021)

Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer
par: Xin Zheng, et autres
Publié: (2021)

Neighborhood disadvantage and individual-level life stressors in relation to breast cancer incidence in US Black women
par: Lauren E. Barber, et autres
Publié: (2021)

Triple-negative breast cancer: treatment challenges and solutions
par: Collignon J, et autres
Publié: (2016)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
par: Zilin Zhang, et autres
Publié: (2021)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
par: Sara Bravaccini, et autres
Publié: (2021)

Encapsulating Halofuginone Hydrobromide in TPGS Polymeric Micelles Enhances Efficacy Against Triple-Negative Breast Cancer Cells
par: Zuo R, et autres
Publié: (2021)

Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
par: Yunhai Li, et autres
Publié: (2021)